Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Biogen Gains FDA Approval For New Alzheimer's Drug, But Medicare Remains A Wild Card

Biogen stock jumped late Friday after the Food and Drug Administration approved its second Alzheimer's treatment, now called Leqembi.

Investors Business Daily

2023 could be a banner year for prescription drugs

There's a large pipeline of promising yet expensive drugs that could get approved.

Axios

IBD Stock Of The Day: How These Issues In 2023 Could Spark, Or Slam, Eli Lilly Stock

Eli Lilly is the IBD Stock Of The Day as the company explores new methods of treating Alzheimer's and obesity, driving LLY stock near highs.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA’s approval of Biogen Alzheimer’s drug slammed in report

U.S. health officials’ approval process for Biogen Inc.’s controversial Alzheimer’s drug was “rife with irregularities,” raising serious concerns about protocol lapses at the agency, congressional investigators said.

Tribune News Service

Congress Targets FDA, Biogen on Alzheimer's Drug Approval

A congressional report finds the FDA's approval process for Biogen's Alzheimer's treatment was 'rife with irregularities' that included 'atypical collaboration.'

The Street

Probe: Alzheimer's drug approval 'rife with irregularities'

The Food and Drug Administration's contentious approval of a questionable Alzheimer's drug is taking another hit

The Independent UK

House report questions FDA’s approval of Alzheimer’s drug

WASHINGTON — A joint investigation released Thursday by House Democrats identified unusual collaboration between Food and Drug Administration officials and drugmaker Biogen, highlighting potential problems in the agency’s approval of the controversial Alzheimer’s drug Aduhelm.

Tribune News Service

Read news from The Economist, FT, and more,
with one subscription

US congressional report slams FDA approval of Alzheimer's drug

Washington (AFP) - The US Food and Drug Administration's approval process for a controversial drug used to treat Alzheimer's was "rife with irregularities," a congressional report said Thursday.

AFP

House report questions FDA's approval of Alzheimer's drug - Roll Call

House Democrats releases a report highlighting potential problems in the FDA's approval of Alzheimer's drug Aduhelm.

Roll Call

The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock

Investors are closely watching two Eli Lilly battles that will unfold in 2023 as LLY stock continues a fevered streak, tacking on new highs.

Investors Business Daily

Lecanemab: Experimental drug is a ray of hope for Alzheimer's disease

On Nov. 30, Eisai and Biogen announced the results of their latest phase 3 clinical trial in Alzheimer’s disease. The verdict: an 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease. The study…

The Conversation

Lots of breakthroughs, still no cure. Do new dementia drugs bring us any closer?

We often hear about dementia breakthroughs in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The New Daily

Lots of 'breakthroughs', still no cure. Do the new dementia drugs bring us any closer?

We often hear about “dementia breakthroughs” in the news – new genes being discovered, new blood tests being developed, new drugs being tested.

The Conversation

Lisa Jarvis: That blockbuster Alzheimer’s drug? It’s not a cure

Biogen Inc. and Eisai Co. caused a stir in September when they announced positive results in a late-stage trial for a closely watched Alzheimer’s drug, lecanemab. Doctors tempered their excitement, though, until they could scrutinize the full peer-reviewed data.

Tribune News Service

Get all your
news in one place.

100’s of premium titles.
One news app.

Al Jazeera

Data shows drug slowing Alzheimer’s but doubts over effect remain

Lecanemab modestly slows disease’s inevitable worsening, but it remains unclear how much of a difference it will make.

Investors Business Daily

Eleven Stocks Turned $10,000 To $261,421 In 11 Months

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

The Street

Biogen Stock Surges As New Drug Offers 'Meaningful Change' For Alzheimer's Patients

"These peer-reviewed, published results show lecanemab will provide patients more time to participate in daily life and live independently," the Alzheimer's Association said.

The New Daily

‘Momentous breakthrough’: New Alzheimer’s drug lives up to bold claims, with caveats

Data supports claims that a new drug reduced cognitive and functional decline in Alzheimer's patients by 27 per cent in a clinical trial.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Stocks Nudge Higher, Powell, Bankman-Fried, Biogen, HPE in Focus -Five Things To Know

Stock futures nudge higher will Powell, jobs data in focus; Powell speech may challenge Fed's new rate hike outlook; Sam Bankman-Fried set for DealBook summit appearance after FTC collapse; Biogen shares jump after promising Alzheimer's treatment data and HPE shares surge after Q4 earnings beat, solid near-term outlook.

WEKU

Study: Alzheimer's drug shows modest success slowing declines in memory, thinking

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

AFP

Alzheimer's drug data shows results but also risks

Tokyo (AFP) - Experts hailed full data Wednesday showing a new drug can slow cognitive decline in Alzheimer's patients, but warned improvements were comparatively small and the treatment can have serious side effects.

Tribune News Service

Alzheimer's drug sparks hot debate over benefits as risks like brain bleeding emerge

Eisai Co. unveiled much-anticipated findings on its experimental Alzheimer’s drug, providing tinder for the hot debate over whether its modest efficacy is worth potential risks that include serious brain bleeding.

Investors Business Daily

Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors

Biogen stock surged Wednesday after partner Eisai unveiled Alzheimer's treatment test results that two doctors reportedly described as "magnificent."

The Independent UK

Drug slows Alzheimer's but can it make a real difference?

New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening

Axios

Safety concerns hang over new Alzheimer's treatment

Two deaths linked to the drug may present a more complicated path to approval.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

500 stories

Lilly

345 stories

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.